United States Office-Based Labs - Market Share Analysis, Industry Trends & Statistics, Growth Forecasts (2026-2031)

The united states office-Based labs market size was valued at USD 15.26 billion in 2025 and is estimated to grow from USD 16.74 billion in 2026 to reach USD 26.69 billion by 2031, at a CAGR of 9.76% during the forecast period (2026-2031). This report is Segmented by Modality (Single-Specialty Office-Based Labs and More), by Service Type (Peripheral Vascular Intervention and More), by Facility Type (Physician-Owned Facilities and More), by Procedure Type (Diagnostic Procedures and More), and by Ownership Model (Independent Physician Ownership and More). The Market Forecasts are Provided in Terms of Value (USD).

United States Office-Based Labs Market Trends and Insights

Migration of Procedures from Hospital Outpatient Departments to Office-Based Labs

The move of suitable vascular and interventional procedures into office settings is a central driver for the United States office-based labs market. The Medicare share of peripheral vascular interventions performed in office-based labs increased from 37.80% in 2019 to 46.50% in 2023. Over the same period, the hospital outpatient department share declined from 35.10% to 27.60%. This pattern shows that the site of care has continued to change even when total payment conditions have been uneven. CMS added 547 procedures to the 2026 ASC Covered Procedures List, expanding the range of outpatient work that can be considered in ambulatory settings as safety standards permit. The phaseout of the inpatient-only list also gives providers a longer path for evaluating procedures outside the hospital when clinical requirements are met. The United States office-based labs market benefits when physicians can plan patient pathways around the most suitable setting rather than a facility model alone.

Lower-Cost Care, Convenient Access, and Point-of-Care Diagnostics

The cost difference between hospital outpatient departments and office or independent laboratory settings remains important for the United States office-based labs market. A 2024 analysis found that the same clinical laboratory tests in hospital outpatient departments cost 3 to 5 times more than tests delivered in physician offices or independent laboratories. The lower-cost setting can also make access more practical when patients need assessment, testing, and follow-up within a shorter care pathway. A 2025 study of Medicare beneficiaries with peripheral artery disease found a median time to treatment of 56 days in office-based settings, compared with 84 days in hospital settings. CLIA-waived point-of-care testing allows qualifying practices to add selected diagnostic services after meeting certificate requirements. This capability can support same-visit clinical decisions without changing the need for appropriate oversight. Hybrid OBL and ASC models add flexibility because operators can use separate reimbursement and operating frameworks on different days, although they cannot operate both models in the same space at the same time.

Reimbursement Pressure, Capital Needs, and State Requirements

Reimbursement volatility is an immediate operating constraint for the United States office-based labs market. Total Medicare Part B payments for peripheral vascular procedures fell 33% from USD 1.40 billion in 2019 to USD 970 million in 2023, even as office-based procedure activity increased. This result shows that rising volumes do not always protect revenue per case when payment rates change. The 2026 Medicare Physician Fee Schedule changed the indirect practice expense methodology, but future payment updates can still alter practice economics. New facilities also face equipment, staffing, compliance, and utilization costs before achieving stable volumes. Certificate-of-need requirements and other state facility rules can add time and uncertainty, particularly in states with active review programs. These barriers can favor established providers with capital, operating experience, and established referral relationships.

Other drivers and restraints analyzed in the detailed report include:

• Peripheral Artery Disease and Cardiovascular Conditions
• Specialty Practice Consolidation and Hybrid Operating Models
• Limited Availability of Qualified Laboratory and Procedural Staff

Segment Analysis

Single-specialty office-based labs held 55.24% of the United States office-based labs market share in 2025. Their position reflects the established presence of vascular and endovascular labs, cardiology-focused labs, and pain management labs. These settings commonly align equipment, staff training, referral patterns, and care protocols around a defined procedure area. The 2026 Physician Fee Schedule changes increased the relevance of office-based cardiology practice expenses for providers that have made these investments. Ophthalmology-focused and gastroenterology-focused facilities can also fit the single-specialty model when procedure volume is sufficient. Orthopedic and spine services are developing as minimally invasive procedures move into suitable outpatient settings. The focused model can simplify clinical governance because the facility operates around a narrower service range.

Hybrid office-based labs are projected to grow at an 11.34% CAGR through 2031. These facilities operate as office-based labs on selected days and as Medicare-certified ASCs on other days through a block-lease arrangement. The approach offers access to distinct operating and reimbursement structures. CMS rules prevent concurrent OBL and ASC use in the same space, so scheduling and licensure must be managed carefully. Multi-specialty models give provider groups a way to broaden their procedure mix and reduce reliance on a single service line. Their success depends on whether local demand and staffing can support several specialties within the same operating structure.

Peripheral vascular intervention represented 44.68% of United States office-based labs market share by service type in 2025. The service line is linked to the established use of office-based care for peripheral artery disease among Medicare beneficiaries. In 2022, 57.20% of peripheral vascular interventions for this population were performed in office-based labs. Vascular specialists can use the setting for assessment, imaging, intervention, and follow-up when a patient meets clinical criteria. Cardiovascular and cardiac services are also gaining attention as more outpatient procedures are reviewed for safe delivery outside hospitals. The expansion of appropriate codes and technology does not remove the need for careful patient selection. It instead gives providers more service-line options within the United States office-based labs market.

Venous intervention is expected to record the fastest service-type growth at an 11.48% CAGR through 2031. The service mix includes radiofrequency ablation, endovenous laser therapy, and sclerotherapy for appropriate patients with chronic venous insufficiency. Endovascular intervention and interventional radiology also benefit from the broader availability of percutaneous and image-guided outpatient procedures. CMS added 547 procedures to the 2026 ASC Covered Procedures List, which supports the continued review of such work in ambulatory care environments. Non-vascular procedures include pain management injections, minor orthopedic interventions, and diagnostic imaging. These services can diversify revenue, although operators must maintain the clinical capabilities required for each procedure category.

Complete Report Scope:

• By Modality
  • Single-Specialty Office-Based Labs
    • Vascular and Endovascular Labs
    • Cardiology-Focused Labs
    • Ophthalmology-Focused Labs
    • Pain Management Labs
    • Gastroenterology-Focused Labs
    • Orthopedic and Spine Labs
    • Other Office-based Labs (Urology Labs, ENT Labs, etc.)
  • Multi-Specialty Office-Based Labs
  • Hybrid Office-Based Labs
• By Service Type
  • Peripheral Vascular Intervention
  • Endovascular Intervention
  • Cardiovascular and Cardiac Services
  • Interventional Radiology
  • Venous Intervention
  • Non-Vascular Office-Based Procedures
• By Facility Type
  • Physician-Owned Facilities
  • Physician-Group Facilities
  • Health-System-Affiliated Facilities
  • Imaging-Center-Affiliated Facilities
  • Private-Equity-Backed Platforms
  • Academic and Research Institutions
• By Procedure Type
  • Diagnostic Procedures
  • Interventional Procedures
  • Others (Minor Surgical Procedures, Rehabilitative Proecdures, etc.)
• By Ownership Model
  • Independent Physician Ownership
  • Health-System Joint Venture
  • Management-Services Organization Model
  • Corporate and Private-Equity Ownership

List of Companies Covered in this Report:

• AmSurg Corp.
• Cardiovascular Centers of America
• Envision Healthcare
• Heart & Vascular Partners
• Heartland Heart & Vascular
• National Cardiovascular Management
• National Cardiovascular Partners
• NovaMed Centers
• Physician's Capital Partners
• SCA Health
• SurgCenter Development LLC
• Surgery Partners, Inc.
• United Surgical Partners International
• Vascular Care Group
• Vascular Surgery Associates, LLC

Additional Benefits:

• The market estimate (ME) sheet in Excel format
• 3 months of analyst support